You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBisoprolol
Accession NumberDB00612  (APRD00257)
TypeSmall Molecule
GroupsApproved
Description

Bisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant β-blocking activity.

Structure
Thumb
Synonyms
(+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
(RS)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
Bisoprolol
Bisoprololum
External Identifiers
  • CL 297939
  • EMD 33512
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-bisoprololtablet10 mgoralAvanstra Inc2011-08-222014-08-21Canada
Ava-bisoprololtablet5 mgoralAvanstra Inc2011-08-222014-08-21Canada
Bisoprololtablet10 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Bisoprololtablet10 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Bisoprololtablet5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Bisoprololtablet5 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Bisoprololtablet10 mgoralSanis Health Inc2012-10-01Not applicableCanada
Bisoprololtablet5 mgoralSanis Health Inc2012-10-01Not applicableCanada
Dom-bisoprololtablet10 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-bisoprololtablet5 mgoralDominion PharmacalNot applicableNot applicableCanada
Monocor -(10mg)tablet10 mgoralBiovail Pharmaceuticals Canada Division Of Biovail Corporation2000-06-222005-03-10Canada
Monocor -(5mg)tablet5 mgoralBiovail Pharmaceuticals Canada Division Of Biovail Corporation2000-06-222009-07-31Canada
Mylan-bisoprololtablet10 mgoralMylan Pharmaceuticals Ulc2012-05-02Not applicableCanada
Mylan-bisoprololtablet5 mgoralMylan Pharmaceuticals Ulc2012-05-02Not applicableCanada
Nu-bisoprololtablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-bisoprololtablet5 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-bisoprololtablet10 mgoralPharmel Inc2008-10-30Not applicableCanada
PHL-bisoprololtablet5 mgoralPharmel Inc2008-10-30Not applicableCanada
PMS-bisoprololtablet5 mgoralPharmascience Inc2007-12-18Not applicableCanada
PMS-bisoprololtablet10 mgoralPharmascience Inc2007-12-18Not applicableCanada
Pro-bisoprolol - 10tablet10 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Pro-bisoprolol - 5tablet5 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Sandoz Bisoprololtablet10 mgoralSandoz Canada Incorporated2003-04-24Not applicableCanada
Sandoz Bisoprololtablet5 mgoralSandoz Canada Incorporated2003-04-24Not applicableCanada
Teva-bisoprololtablet10 mgoralTeva Canada Limited2005-10-07Not applicableCanada
Teva-bisoprololtablet5 mgoralTeva Canada Limited2005-10-07Not applicableCanada
Zebetatablet, film coated5 mg/1oralTeva Women's Health, Inc.1992-07-31Not applicableUs
Zebetatablet, film coated10 mg/1oralTeva Women's Health, Inc.1992-07-31Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bisoprololtablet10 mgoralApotex Inc2004-08-10Not applicableCanada
Apo-bisoprololtablet5 mgoralApotex Inc2004-08-10Not applicableCanada
Bisoprolol Fumaratetablet, film coated10 mg/1oralCitron Pharma LLC2006-12-27Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2004-06-01Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralAurobindo Pharma Limited2006-12-27Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralRebel Distributors Corp2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralCitron Pharma LLC2006-12-27Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2012-09-24Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2009-08-07Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2012-09-24Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2009-07-23Not applicableUs
Bisoprolol Fumaratetablet, coated10 mg/1oralEon Labs, Inc.2000-11-16Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralCarilion Materials Management2009-09-21Not applicableUs
Bisoprolol Fumaratetablet10 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, coated5 mg/1oralEon Labs, Inc.2000-11-16Not applicableUs
Bisoprolol Fumaratetablet, coated5 mg/1oralAmerican Health Packaging2011-08-01Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralbryant ranch prepack2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2004-06-01Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralAurobindo Pharma Limited2006-12-27Not applicableUs
Bisoprolol Fumaratetablet10 mg/1oralRebel Distributors Corp2009-09-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CardicorBayer
ConcorMerck
ConcoreMerck
DetensielMerck Santé
EmconcorMerck
EmcorMerck
EuradalLacer
IsotenMeda
MonocorBiovail Pharmaceuticals
SoprolHelsinn
Brand mixtures
NameLabellerIngredients
Bisoprolol Fumarate and HydrochlorothiazideEon Labs, Inc.
ZiacTeva Women's Health, Inc.
Salts
Name/CASStructureProperties
Bisoprolol Fumarate
ThumbNot applicableDBSALT001015
Categories
UNIIY41JS2NL6U
CAS number66722-44-9
WeightAverage: 325.443
Monoisotopic: 325.225308485
Chemical FormulaC18H31NO4
InChI KeyInChIKey=VHYCDWMUTMEGQY-UHFFFAOYSA-N
InChI
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
IUPAC Name
1-[(propan-2-yl)amino]-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzylethers
Direct ParentBenzylethers
Alternative Parents
Substituents
  • Benzylether
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
PharmacodynamicsBisoprolol is a competitive, cardioselective β1-adrenergic antagonist. Activation of β1-receptors (located mainly in the heart) by epinephrine increases heart rate and the blood pressure causing the heart to consume more oxygen. β1-adrenergic blocking agents such as bisopolol lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. They are routinely prescribed in patients with ischemic heart disease. In addition, β1-selective blockers prevent the release of renin, a hormone produced by the kidneys causes constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane-stabilizing activity.
Mechanism of actionBisoprolol selectively blocks catecholamine stimulation of β1-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. At higher doses (e.g. 20 mg and greater) bisoprolol may competitively block β2-adrenergic receptors in bronchial and vascular smooth muscle causing bronchospasm and vasodilation.
Related Articles
AbsorptionWell absorbed. Bioavailability > 80%. Absorption is not affected by food. Peak plasma concentrations occur within 2-4 hours.
Volume of distributionNot Available
Protein bindingBinding to serum proteins is approximately 30%
Metabolism

Approximately 50% of the dose is metabolized primarily metabolized by CYP3A4 to inactive metabolites. In vitro studies have shown that bisoprolol is also metabolized by CYP2D6 though this does not appear to be clinically significant. Approximately half the administered dose is excreted in unchanged in urine.

Route of eliminationEliminated equally by renal and non-renal pathways. Approximately 50% of the total orally administered dose is excreted unchanged in urine with the remainder appearing as inactive metabolites. Less than 2% of the dose is excreted in the feces.
Half life9-12 hours; prolonged in the elderly and those with decreased renal function
ClearanceNot Available
ToxicityOral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bisoprolol Action PathwayDrug actionSMP00300
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier-0.9077
Caco-2 permeable+0.6149
P-glycoprotein substrateSubstrate0.7785
P-glycoprotein inhibitor INon-inhibitor0.807
P-glycoprotein inhibitor IINon-inhibitor0.7821
Renal organic cation transporterNon-inhibitor0.8568
CYP450 2C9 substrateNon-substrate0.8134
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6113
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9485
CYP450 3A4 inhibitorNon-inhibitor0.8373
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9766
Ames testNon AMES toxic0.9064
CarcinogenicityNon-carcinogens0.9267
BiodegradationNot ready biodegradable0.8962
Rat acute toxicity2.0089 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7877
hERG inhibition (predictor II)Non-inhibitor0.6611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aurobindo pharma ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Unichem pharmaceuticals (usa) inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral5 mg/1
Tablet, coatedoral10 mg/1
Tablet, coatedoral5 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral
Tablet, coatedoral
Tablet, film coatedoral
Tabletoral10 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Condylox 0.5% Gel 3.5 gm Tube304.93USD tube
Condylox 0.5% Solution 3.5ml Bottle143.4USD bottle
Condylox 0.5% gel97.73USD g
Zebeta 10 mg tablet3.6USD tablet
Zebeta 5 mg tablet3.6USD tablet
Bisoprolol fumarate 5 mg tablet1.78USD tablet
Bisoprolol fumarate 10 mg tablet1.24USD tablet
Bisoprolol-Hydrochlorothiazide 10-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 2.5-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 5-6.25 mg tablet1.19USD tablet
Apo-Bisoprolol 10 mg Tablet0.38USD tablet
Novo-Bisoprolol 10 mg Tablet0.38USD tablet
Pms-Bisoprolol 10 mg Tablet0.38USD tablet
Sandoz Bisoprolol 10 mg Tablet0.38USD tablet
Apo-Bisoprolol 5 mg Tablet0.23USD tablet
Novo-Bisoprolol 5 mg Tablet0.23USD tablet
Pms-Bisoprolol 5 mg Tablet0.23USD tablet
Sandoz Bisoprolol 5 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point100 °CPhysProp
water solubility2240 mg/LNot Available
logP1.87RECANATINI,M (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0707 mg/mLALOGPS
logP2.3ALOGPS
logP2.2ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity92.15 m3·mol-1ChemAxon
Polarizability38.5 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yoshihiro Iwao, Katsuyuki Ookubo, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa, “Adhesive Pharmaceutical Preparation Containing Bisoprolol.” U.S. Patent US20090169604, issued July 02, 2009.

US20090169604
General ReferencesNot Available
External Links
ATC CodesC07AB07C07AB57C07BB07C07FB07C09BX02
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.1 KB)
Interactions
Drug Interactions
Drug
AcepromazineAcepromazine may increase the hypotensive activities of Bisoprolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acetylcholine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.
AlfuzosinBisoprolol may increase the orthostatic hypotensive activities of Alfuzosin.
AmifostineBisoprolol may increase the hypotensive activities of Amifostine.
AmiodaroneAmiodarone may increase the bradycardic activities of Bisoprolol.
AprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Aprepitant.
BexaroteneThe serum concentration of Bisoprolol can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Bisoprolol can be decreased when it is combined with Bosentan.
BretyliumBretylium may increase the bradycardic activities of Bisoprolol.
BrimonidineBrimonidine may increase the antihypertensive activities of Bisoprolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bisoprolol.
ButabarbitalThe serum concentration of Bisoprolol can be decreased when it is combined with Butabarbital.
ButethalThe serum concentration of Bisoprolol can be decreased when it is combined with Butethal.
CabergolineBisoprolol may increase the vasoconstricting activities of Cabergoline.
CarbacholThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbachol.
CeritinibBisoprolol may increase the bradycardic activities of Ceritinib.
ChloroquineThe metabolism of Bisoprolol can be decreased when combined with Chloroquine.
ChlorpropamideBisoprolol may increase the hypoglycemic activities of Chlorpropamide.
ConivaptanThe serum concentration of Bisoprolol can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Bisoprolol can be decreased when it is combined with Deferasirox.
DiazoxideDiazoxide may increase the hypotensive activities of Bisoprolol.
DigoxinBisoprolol may increase the bradycardic activities of Digoxin.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
DipyridamoleDipyridamole may increase the bradycardic activities of Bisoprolol.
DisopyramideDisopyramide may increase the bradycardic activities of Bisoprolol.
DronedaroneDronedarone may increase the bradycardic activities of Bisoprolol.
DuloxetineBisoprolol may increase the orthostatic hypotensive activities of Duloxetine.
EsmololEsmolol may increase the bradycardic activities of Bisoprolol.
FingolimodBisoprolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bisoprolol.
FluconazoleThe metabolism of Bisoprolol can be decreased when combined with Fluconazole.
FosaprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Bisoprolol can be increased when it is combined with Fusidic Acid.
HeptabarbitalThe serum concentration of Bisoprolol can be decreased when it is combined with Heptabarbital.
HexobarbitalThe serum concentration of Bisoprolol can be decreased when it is combined with Hexobarbital.
IdelalisibThe serum concentration of Bisoprolol can be increased when it is combined with Idelalisib.
InfliximabInfliximab may decrease the antihypertensive activities of Bisoprolol.
IvabradineBisoprolol may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Bisoprolol can be increased when it is combined with Ivacaftor.
LacosamideBisoprolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LevodopaBisoprolol may increase the orthostatic hypotensive activities of Levodopa.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bisoprolol.
LuliconazoleThe serum concentration of Bisoprolol can be increased when it is combined with Luliconazole.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bisoprolol.
MethacholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methacholine.
MethohexitalThe serum concentration of Bisoprolol can be decreased when it is combined with Methohexital.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bisoprolol.
MidodrineBisoprolol may increase the bradycardic activities of Midodrine.
MifepristoneThe serum concentration of Bisoprolol can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Bisoprolol can be decreased when it is combined with Mitotane.
MolsidomineMolsidomine may increase the hypotensive activities of Bisoprolol.
MoxonidineMoxonidine may increase the hypotensive activities of Bisoprolol.
NelfinavirThe metabolism of Bisoprolol can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Bisoprolol can be increased when it is combined with Netupitant.
NicorandilNicorandil may increase the hypotensive activities of Bisoprolol.
NifedipineNifedipine may increase the hypotensive activities of Bisoprolol.
ObinutuzumabBisoprolol may increase the hypotensive activities of Obinutuzumab.
OctreotideOctreotide may increase the bradycardic activities of Bisoprolol.
OrciprenalineBisoprolol may decrease the activities of Orciprenaline.
PalbociclibThe serum concentration of Bisoprolol can be increased when it is combined with Palbociclib.
PentobarbitalThe serum concentration of Bisoprolol can be decreased when it is combined with Pentobarbital.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bisoprolol.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Bisoprolol.
PhenytoinThe metabolism of Bisoprolol can be increased when combined with Phenytoin.
PrazosinBisoprolol may increase the orthostatic hypotensive activities of Prazosin.
PrimidoneThe serum concentration of Bisoprolol can be decreased when it is combined with Primidone.
PropafenoneThe serum concentration of Bisoprolol can be increased when it is combined with Propafenone.
QuinineQuinine may increase the hypotensive activities of Bisoprolol.
RegorafenibRegorafenib may increase the bradycardic activities of Bisoprolol.
ReserpineReserpine may increase the hypotensive activities of Bisoprolol.
RisperidoneBisoprolol may increase the hypotensive activities of Risperidone.
RituximabBisoprolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Bisoprolol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Bisoprolol.
SecobarbitalThe serum concentration of Bisoprolol can be decreased when it is combined with Secobarbital.
SiltuximabThe serum concentration of Bisoprolol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bisoprolol can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Bisoprolol can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Bisoprolol can be increased when it is combined with Stiripentol.
SufentanilSufentanil may increase the bradycardic activities of Bisoprolol.
TacrineTacrine may increase the bradycardic activities of Bisoprolol.
TadalafilTadalafil may increase the antihypertensive activities of Bisoprolol.
TheophyllineBisoprolol may decrease the activities of Theophylline.
TocilizumabThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Bisoprolol.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Bisoprolol.
TreprostinilTreprostinil may increase the hypotensive activities of Bisoprolol.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bisoprolol.
VardenafilVardenafil may increase the antihypertensive activities of Bisoprolol.
YohimbineYohimbine may decrease the antihypertensive activities of Bisoprolol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Breed JG, Ciampricotti R, Tromp GP, Valster FA, Lageweg E, Van Bortel LM: Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol. 1992;20(5):750-5. [PubMed:1280737 ]
  2. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145 ]
  3. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4. [PubMed:16325050 ]
  4. Lipworth BJ, Irvine NA, McDevitt DG: A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135-9. [PubMed:1676675 ]
  5. Mauz AB, Pelzer H: Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol. J Cardiovasc Pharmacol. 1990 Mar;15(3):421-7. [PubMed:1691366 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145 ]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107 ]
  3. Motomura S, Reinhard-Zerkowski H, Daul A, Brodde OE: On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J. 1990 Mar;119(3 Pt 1):608-19. [PubMed:1968697 ]
  4. Brodde OE: Bisoprolol (EMD 33512), a highly selective beta 1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S29-35. [PubMed:2439795 ]
  5. Daul A, Johnston T, Reher M, Kruger M, Brodde OE: Differential haemodynamic effects induced by beta 1-(bisoprolol) or beta 2-(ICI 118,551) adrenoceptor blockade in man. J Hypertens Suppl. 1986 Dec;4(6):S99-102. [PubMed:2886573 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980 ]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205 ]
  3. Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B, Igawa A, Inoue H: Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005 Nov;46(5):713-20. [PubMed:16220080 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980 ]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23